Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print          Annual reports

Tuesday 11 May, 2021

GlaxoSmithKline PLC

EMTN Prospectus

RNS Number : 2310Y
GlaxoSmithKline PLC
11 May 2021

Publication of Base Prospectus


The following base prospectus dated 10 May 2021 has been approved by the Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from: .

For further information, please contact:

GlaxoSmithKline plc
980 Great West Road
United Kingdom


UK Media enquiries:

Mary Hinks-Edwards

David Mawdsley

Simon Steel

+44 (0) 20 8047 5502

+44 (0) 20 8047 5564

+44 (0) 20 8047 3763

European Analyst/Investor enquiries:

James Dodwell

Danielle Smith

+44 (0) 20 8047 2406

+44 (0) 20 8047 0932


Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t